BofA raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $111 from $100 and keeps a Buy rating on the shares. The firm adjusted several targets in conjunction with its Q1 preview for its large-cap pharma and small-to-mid cap biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors
- Ionis Pharmaceuticals management to meet with Oppenheimer
- Ionis: Olezarsen’s Expanded Global Opportunity and Strengthened Royalty Streams Support Reiterated Buy and $120 Target
- Arrowhead price target lowered to $81 from $84 at BofA
- Ionis Pharmaceuticals price target raised to $106 from $95 at Barclays